Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope a bit of awareness doesn't draw in the bottom of the barrel here.....
Gtxi. Why today's CEO sale of shares
Vintage sheepherder play......
He sells for a miniscule profit and immediately stock is in the red for all other followers....vintage....
love the willing it lower tactic with buy in cheaper later nonsense.......
The company is not transparent......why can it not announce when results will be released....never before heard of a legit bio saying maybe here or there or somewhere.
Trading has fallen off the map in ONCS.....with updated results due this month it would be nice if someone followed the stock.............
A trade killer.....this news hopefully won't effect lo ng term but it surely will significantly delay progress...........unfortunate but the price has been capped for the foreseeable future...
Will take a hit this morning...
.....Cytokinetics Provides Update on BENEFIT-ALS
Press Release: Cytokinetics, Inc. – 54 minutes ago....Email0
Share0Print.....RELATED QUOTES..Symbol Price Change
CYTK 12.81
......
South San Francisco, CA, July 8, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today an update on the conduct of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). BENEFIT-ALS is a Phase IIb, multinational, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the safety, tolerability and potential efficacy of tirasemtiv, a fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis (ALS).
BENEFIT-ALS is currently designed to enroll up to 500 patients with ALS. To date, over 450 patients have been enrolled in this study. The primary analysis of BENEFIT-ALS will compare the mean change from baseline in the ALS Functional Rating Scale in its revised form, or ALSFRS-R (a clinically validated instrument designed to measure disease progression and changes in functional status), in patients receiving tirasemtiv versus those receiving placebo.
Cytokinetics was recently informed by its data management vendor that a programming error in the electronic data capture system controlling study drug assignment caused 58 patients initially randomized to and treated with tirasemtiv to receive placebo instead at a certain study visit and for the remainder of the study. No patients randomized to placebo were dispensed incorrect treatment. Cytokinetics and all clinical trial site personnel remain blinded to the specific patients affected by the error.
Since the error was detected, the company has taken steps to ensure that no further incorrect study drug assignments have occurred and the programming error in the electronic data capture system controlling study drug assignment has been corrected. In addition, the company recently convened an ad hoc meeting of the study`s Data Safety Monitoring Board (DSMB) to assess whether the error in dispensing study drug had impacted the safety of the 58 affected patients. After review of the relevant safety data from BENEFIT-ALS, the DSMB reported no concerns regarding patient safety.
Cytokinetics is in communication with regulatory authorities regarding how best to respond to the error in drug assignment in order to preserve the intended scientific value of BENEFIT-ALS. The company continues to enroll patients in the study under the current protocol and may amend the protocol to allow increased enrollment. Following further communications with regulatory authorities, Cytokinetics expects to provide updated guidance relating to the conduct of BENEFIT-ALS, which may include revisions to the timing of publicly available results from the study as well as to the projected costs of the study.
Dude you pop up out of nowhere, an IHUB free account newbie, with posts on this board touting a new next best thing daily..........at least if you want to rip on people like me ....stop being a chisler and get a premium account unless your savvy picks have left you with no money...
Last week it was AXU and now its JASO......wow........
So many boards have folks crazy for this as an undervalued gem.....looks like a great story ahead but why can't it break $1.40 resistance....strange as no significant sellers?/
So quiet here....I guess the OTC status is a killer in terms of awareness. Great trial updates in two weeks and no buyers.............sad
Not surprised at all that the dip was quickly bought.......tremendous values at these heavily discounted levels for ONCS. They will not last long....new highs coming soon.
ONCS......will be a trend setter in the next wave of great bio companies. Momentum and interest will continue to pick up here.....they have a potential homerun drug in late stage for a billion dollar market worldwide- melanoma
There is no way to justify not buying in at these levels......all evidence to date suggests a safe & effective melanoma treatment that will surpass the success rate of what's currently available. If you look at the enormous worldwide market for this disease, no way can you justify a market cap at these low levels for ONCS.
Where else can you find a value like this.....a robust late stage pipeline oriented to a huge worldwide market .....this is a gift at these levels.....
I wouldn't be concerned with daily dips.....OTC is always a bumpy ride but also provides rich rewards.......a nice spike is headed our way....money will be piling in.....July 18 is the melaloma symposium...
I believe ONCS will prove the naysayers wrong......this will be signficantly higher in short order.....trials updates will only affirm the efficacy of their melanoma treatment as a game changer....hold on tight....it won't be long.
Oh boy...momentum and interest really picking up into the July results if they are even available as some YMB poster said Amy @ IR said not so fast perhaps....
They are really inspiring buying here. Again, if this was such a great treatment why is no one buying....
It always feels good to have your view substantiated by a further deteriorating stock price. Hang in there folks....ONCS will deliver....LOL
More pain to come with this pos
Sheff is a great trader but I wonder if his OTC pick wasn't more the result of several of his followers salivating for him to choose ONCS as opposed to him being a real ONCS fan. Lot's of pumping of ONCS was done a few motnhs back only for the true colors of this POS to show now.....a true worthless penny stock....24 cents a share on continued selling pressure that is relentless...
ONCS is a penny POS and nothing more. Never seen another bio with a self proclaimed first in class treatment for a cancer trade down relentlessly to pennies a few weeks before a huge conference. This is not trading a $1.20 its .23 cents. LOL
Then answer me why it's trading at .23 cents and ZIOP is many fold higher. Where there is smoke there is fire. The market values this as a penny stock.....that is the bottom line....IMO mgt. is a joke.........
so we are to believe this .24 cent stock is the next big thing in bio....LOL..........
weeks away from trail updates and relentless selling and dilution.........
hmmmm....maybe not the next AMgen....yuo think????
This POS is headed to teens
So nothing new on the 18th another swerve I guess....previous results.....$3 per share.....are you for real.....this thing can't get to . 35 cents.....they will reverse split to get there as no one is buying this POS....
The only thing that tells story is the price which is in the toilet.....don't you think if there was something to this science that someone would buy this up to higher levels. I see no buying to offset dilution...
Does this POS have a CE mark...If so, what the F are they doing with it.........they've had it for many many months now....Company is a POS IMO and does not give two hoots about you folks.....can;t take their greedy foot off the pedal so you could at least get to .35 cents....worst bio I've seen in decades....
bashing is appropriate when a company sells shares into its first mini run in months so that the boss can buy a designer suit for more personal photos to upload to the site. like i said the site and boss dazzle you with glitz and flash and fancy graphics......yet no one can argue that a 25 cent stock speaks for itself.....it would be priced higher if it wasn't a POS... I see no big pharma involvement...only a brazen and cocky mgt. that will assuredly think they don't need anyone ...which is true if they keep diluting....
The pundit has an ego the size of this planet and is clearly a spin doctor......figuring his polished wardrobe and glossy HD photos will convince folks this co is a winner.....
This is another in a long line of companies that string folks along for years with teasers of partnership talks, etc, etc. never to transpire.
Looks like heavy company unloading to rape the small profits hard working investors earned on the mover above 30 cents.
POS
Did you ever seen Pundit's blog....Never seen an exec as boldly full of himself with a photo almost larger than your entire screen..
This co is all flash and no substance...classic mesmerize them with an exotic website and cutting edge graphics and lure them in hook, line and sinker.
this is a POS OTC stock trading for a quarter. Any co. that had a self proclaimed cure would not be a laughable OTC...
Company is garbage IMO and unfortunately the chants of many OTC lovers persuaded savvy traders to join here. Mgt only good for tweeting
Thus my handle....comments are just that....whatever at the time....
but ONCS is not trading well....that is a fact and concerning it should be to all....
The CEO is IMO part of the problem,....
Then why post here if you don't expect these catalysts to move the stock? Do you just get your jollies posting on the ONCS board while the science takes years to ripen enough to monetize the value....
so you didn't expect any buying a few weeks before an anticipated release of perhaps magnificant results? did you expect to the contrary this relentless sell off. Pundit is a baffoon not someone who inspires faith...
This has become a laughing stock.......no pun intended.....supposed interim results right around the corner yet not a sole buying this at heavily discounted prices.....
a .26 cent stock that obviously has earned zero respect in the marketplace......
the game was the trade to the low 30 cent range......this looks done...
Basically this is a dead stock right now....zero buying with a catalyst a few weeks away. Very disappointing and won't be surprised to seee certain traders and their folks bail based on how poorly this is trading........very disappointing..
market not withstanding....this has been a much longer period of settling and consolidation at these levels than I anticipated. Catalyst is only a few more weeks away .....so I am starting to be quite surprised where this is trading and wonder where the pressure is coming from still....the science looks great and the stock is not showing it at all....
ONCS.......consolidation should be done here.....its settled in and should move soon ....catalyst nearing